Onyx Pharmaceuticals to Webcast Analyst Briefing

Contacts:
Julie Wood           Alex Santos
510-597-6505     510-597-6504

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced today that it will webcast a post-ASCO analyst briefing on Thursday, May 26, 2005, beginning at 4:30 p.m. Eastern Time.  Clinical investigators participating in the meeting include:

• Bernard J. Escudier, M.D. of the Institut Gustave Roussy, France
  
• Mark J. Ratain, M.D. of the University of Chicago
  
• Timothy G. Q. Eisen, M.D. of The Royal Marsden Hospital in England 
  
• Keith T. Flaherty, M.D. of the University of Pennsylvania in Philadelphia 

The physicians will review recently reported clinical data for the investigational drug, sorafenib, being developed in collaboration with Bayer Pharmaceuticals Corporation.  Interested parties may access a live webcast of the presentation by clicking on the link below:

http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=112065&eventID=1048584

or by dialing 617-786-4513 and using the passcode 36654325.  A replay of the presentation will be available on the Onyx website or by dialing 617-801-6888 and using the passcode 25155661 approximately one hour after the teleconference concludes.  The replay will be available through June 26, 2005.

Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer.  With its collaborators, the company is developing small molecule drugs, including sorafenib with Bayer Pharmaceuticals Corporation.   For more information about Onyx's pipeline and activities, visit the company's website at www.onyx-pharm.com.

Back to 2005 Press Releases